Adjunctive Subgingival Pomegranate Peel Extract Gel for Stage II-III Periodontitis (POME-PERIO)
Adjunctive Subgingival Pomegranate Peel Extract Gel for Stage II-III Periodontitis: A Randomized Split-Mouth Trial
This randomized, triple-blind, placebo-controlled split-mouth clinical trial aims to evaluate the clinical and biochemical efficacy of subgingival pomegranate peel extract gel as an adjunct to scaling and root planing (SRP) in the treatment of Stage II-III periodontitis.
Thirty-two participants diagnosed with Stage II-III periodontitis will receive SRP in all selected periodontal sites. Test sites will receive locally delivered pomegranate peel extract gel, while contralateral control sites will receive a placebo gel. Clinical periodontal parameters, including probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), bleeding on probing (BOP), and gingival crevicular fluid levels of matrix metalloproteinase-8 (MMP-8), will be assessed at baseline, 1 month, 3 months, and 6 months to evaluate whether adjunctive pomegranate peel extract gel improves periodontal healing compared with SRP alone.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Gehad Samy, BDS, MSc, PhD
- Phone Number: +201092710515
- Email: gehadasaad.26@azhar.edu.eg
Study Locations
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egypt
- Recruiting
- Faculty of Dental Medicine for Girls, Al-Azhar University
-
Contact:
- Gehad Samy, BDS, MSc, PhD
- Phone Number: +201092710515
- Email: gehadasaad.26@azhar.edu.eg
-
Principal Investigator:
- Gehad Samy, BDS, MSc, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults aged 30 to 60 years.
- Systemically healthy individuals.
- Diagnosis of Stage II or Stage III periodontitis according to the 2018 Classification of Periodontal and Peri-Implant Diseases and Conditions.
- Presence of at least 20 natural teeth.
- Presence of at least two non-adjacent periodontal pockets (≥5 mm) located in different quadrants suitable for split-mouth allocation.
- Clinical attachment loss consistent with Stage II or Stage III periodontitis.
- Ability and willingness to comply with the study protocol and attend all follow-up visits.
- Provision of written informed consent.
Exclusion Criteria:
- Current smokers or users of any tobacco products.
- Pregnant or lactating women.
- Patients with systemic diseases known to affect periodontal status or wound healing (e.g., uncontrolled diabetes mellitus, immunodeficiency disorders, osteoporosis requiring antiresorptive therapy).
- Use of systemic antibiotics, corticosteroids, immunosuppressive agents, or non-steroidal anti-inflammatory drugs within the previous 3 months.
- Periodontal therapy received within the previous 6 months.
- History of allergy or hypersensitivity to pomegranate or any component of the study materials.
- Orthodontic treatment during the study period.
- Participation in another clinical trial within the previous 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pomegranate Peel Extract Gel
Periodontal sites receive scaling and root planing followed by subgingival application of pomegranate peel extract gel.
|
Locally delivered subgingival gel containing pomegranate peel extract administered after scaling and root planing.
|
|
Placebo Comparator: Placebo Gel
Periodontal sites receive scaling and root planing followed by subgingival application of placebo gel with identical appearance and consistency.
|
Placebo gel without active ingredient, identical in appearance and consistency to the experimental gel, administered after scaling and root planing.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Probing Pocket Depth (PPD)
Time Frame: Baseline, 1 month, 3 months, and 6 months
|
Change in probing pocket depth (PPD), measured in millimeters using a calibrated periodontal probe at the selected periodontal sites.
|
Baseline, 1 month, 3 months, and 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Clinical Attachment Level (CAL)
Time Frame: Baseline, 1 month, 3 months, and 6 months
|
Change in clinical attachment level (CAL), measured in millimeters using a calibrated periodontal probe at the selected periodontal sites.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Plaque Index (PI)
Time Frame: Baseline, 1 month, 3 months, and 6 months
|
Change in plaque index (PI) assessed using the Silness and Löe Plaque Index.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Gingival Index (GI)
Time Frame: Baseline, 1 month, 3 months, and 6 months
|
Change in gingival index (GI) assessed using the Löe and Silness Gingival Index.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Bleeding on Probing (BOP)
Time Frame: Baseline, 1 month, 3 months, and 6 months
|
Change in bleeding on probing (BOP), assessed as the presence or absence of bleeding following gentle periodontal probing.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Gingival Crevicular Fluid Matrix Metalloproteinase-8 (MMP-8) Levels
Time Frame: Baseline, 1 month, 3 months, and 6 months
|
Change in gingival crevicular fluid matrix metalloproteinase-8 (MMP-8) concentration measured using enzyme-linked immunosorbent assay (ELISA).
|
Baseline, 1 month, 3 months, and 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Luchian I, Goriuc A, Sandu D, Covasa M. The Role of Matrix Metalloproteinases (MMP-8, MMP-9, MMP-13) in Periodontal and Peri-Implant Pathological Processes. Int J Mol Sci. 2022 Feb 4;23(3):1806. doi: 10.3390/ijms23031806.
- Tyagi P, Dodwad V, Kukreja BJ, Kukreja P. A comparison of the efficacy of scaling and root planning with application of pomegranate chip, pomegranate gel, and scaling and root planing in sufferers with adult periodontitis - A prospective study. J Indian Soc Periodontol. 2021 Jan-Feb;25(1):41-46. doi: 10.4103/jisp.jisp_243_20. Epub 2021 Jan 7.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P-PD-26-09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.